Key result
Ibutilide reduces defibrillation current requirements ~23% vs placebo in dogs.
Why the study?
The effect of ibutilide, a type III antiarrhythmic agent that activates the sodium component of the plateau inward current, on defibrillation current and energy requirements was investigated.
Absolute Event Rate: 10.9% vs 14.1%
p-value: p=< 0.005
No takes yet. Share an insight, caveat, or question.
Animal data suggest potential to lower defibrillation thresholds; requires human trials before clinical consideration.
Wesley et al. (1993) studied Ventricular fibrillation (n=15). Ibutilide vs. Saline placebo was evaluated on Current requirement for defibrillation in Amperes (Protocol I) (p=< 0.005). Ibutilide significantly reduced the current requirements for defibrillation in dogs compared with placebo (10.9 +/- 4.5 A vs 14.1 +/- 5.6 A; P<0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: